MEIP MEI PHARMA INC Business Restructuring 8-K Filing 2024 - Strategic Alternatives and Workforce Reduction MEI Pharma, Inc. announced strategic alternatives including potential transactions and a possible wind-down of the company, leading to a reduction-in-force and discontinuation of clinical development of voruciclib, resulting in expected restructuring charges of $5.8 million. The President and Chief Medical Officer will be leaving the company, and a new Acting CEO has been appointed.Get access to all SEC 8-K filings of the MEI PHARMA INC